XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     $ 36,161,000 $ 60,827,000  
Deferred Revenue     16,495,000   $ 12,739,000
Drug Product Revenue [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     2,109,000 7,594,000  
Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transaction price, variable consideration from estimated future co-development billing     0    
Japan [Member] | Drug Product Revenue [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     $ 1,700,000 9,800,000  
Astellas Agreement [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received   $ 172,600,000      
Additional consideration based on net sales description     the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     $ 105,100,000    
Changes in revenue from changes to estimated variable consideration     $ 0    
Astellas Agreement [Member] | Europe [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received $ 745,000,000.0        
Additional consideration based on net sales description     low 20% range    
Aggregate consideration received excluding drug product revenue     $ 685,000,000.0    
Transaction price, variable consideration from estimated future co-development billing     5,800,000    
Percentage of joint development costs committed to fund 50.00%        
Transaction price and allocated to performance obligations       $ 25,000,000.0  
Changes in revenue from changes to estimated variable consideration     $ 0